Cargando…

Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers

BACKGROUND: Aim of the study is to evaluate the role of ultrasound guided fine needle aspiration cytology (FNAC) in the restaging of node positive breast cancer after preoperative systemic therapy (PST). METHODS: From January 2016 – October 2020 106 node positive stage IIA-IIIC breast cancer cases u...

Descripción completa

Detalles Bibliográficos
Autores principales: Līcīte, Baiba, Irmejs, Arvīds, Maksimenko, Jeļena, Loža, Pēteris, Trofimovičs, Genādijs, Miklaševičs, Edvīns, Nazarovs, Jurijs, Romanovska, Māra, Deičmane, Justīne, Irmejs, Reinis, Purkalne, Gunta, Gardovskis, Jānis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262039/
https://www.ncbi.nlm.nih.gov/pubmed/34233740
http://dx.doi.org/10.1186/s13053-021-00187-w
_version_ 1783719118065631232
author Līcīte, Baiba
Irmejs, Arvīds
Maksimenko, Jeļena
Loža, Pēteris
Trofimovičs, Genādijs
Miklaševičs, Edvīns
Nazarovs, Jurijs
Romanovska, Māra
Deičmane, Justīne
Irmejs, Reinis
Purkalne, Gunta
Gardovskis, Jānis
author_facet Līcīte, Baiba
Irmejs, Arvīds
Maksimenko, Jeļena
Loža, Pēteris
Trofimovičs, Genādijs
Miklaševičs, Edvīns
Nazarovs, Jurijs
Romanovska, Māra
Deičmane, Justīne
Irmejs, Reinis
Purkalne, Gunta
Gardovskis, Jānis
author_sort Līcīte, Baiba
collection PubMed
description BACKGROUND: Aim of the study is to evaluate the role of ultrasound guided fine needle aspiration cytology (FNAC) in the restaging of node positive breast cancer after preoperative systemic therapy (PST). METHODS: From January 2016 – October 2020 106 node positive stage IIA-IIIC breast cancer cases undergoing PST were included in the study. 18 (17 %) were carriers of pathogenic variant in BRCA1/2. After PST restaging of axilla was performed with ultrasound and FNAC of the marked and/or the most suspicious axillary node. In 72/106 cases axilla conserving surgery and in 34/106 cases axillary lymph node dissection (ALND) was performed. RESULTS: False Positive Rate (FPR) of FNAC after PST in whole cohort and BRCA1/2 positive subgroup is 8 and 0 % and False Negative Rate (FNR) – 43 and 18 % respectively. Overall Sensitivity − 55 %, specificity- 93 %, accuracy 70 %. CONCLUSION: FNAC after PST has low FPR and is useful to predict residual axillary disease and to streamline surgical decision making regarding ALND both in BRCA1/2 positive and negative subgroups. FNR is high in overall cohort and FNAC alone are not able to predict ypCR and omission of further axillary surgery. However, FNAC performance in BRCA1/2 positive subgroup is more promising and further research with larger number of cases is necessary to confirm the results.
format Online
Article
Text
id pubmed-8262039
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82620392021-07-08 Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers Līcīte, Baiba Irmejs, Arvīds Maksimenko, Jeļena Loža, Pēteris Trofimovičs, Genādijs Miklaševičs, Edvīns Nazarovs, Jurijs Romanovska, Māra Deičmane, Justīne Irmejs, Reinis Purkalne, Gunta Gardovskis, Jānis Hered Cancer Clin Pract Research BACKGROUND: Aim of the study is to evaluate the role of ultrasound guided fine needle aspiration cytology (FNAC) in the restaging of node positive breast cancer after preoperative systemic therapy (PST). METHODS: From January 2016 – October 2020 106 node positive stage IIA-IIIC breast cancer cases undergoing PST were included in the study. 18 (17 %) were carriers of pathogenic variant in BRCA1/2. After PST restaging of axilla was performed with ultrasound and FNAC of the marked and/or the most suspicious axillary node. In 72/106 cases axilla conserving surgery and in 34/106 cases axillary lymph node dissection (ALND) was performed. RESULTS: False Positive Rate (FPR) of FNAC after PST in whole cohort and BRCA1/2 positive subgroup is 8 and 0 % and False Negative Rate (FNR) – 43 and 18 % respectively. Overall Sensitivity − 55 %, specificity- 93 %, accuracy 70 %. CONCLUSION: FNAC after PST has low FPR and is useful to predict residual axillary disease and to streamline surgical decision making regarding ALND both in BRCA1/2 positive and negative subgroups. FNR is high in overall cohort and FNAC alone are not able to predict ypCR and omission of further axillary surgery. However, FNAC performance in BRCA1/2 positive subgroup is more promising and further research with larger number of cases is necessary to confirm the results. BioMed Central 2021-07-07 /pmc/articles/PMC8262039/ /pubmed/34233740 http://dx.doi.org/10.1186/s13053-021-00187-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Līcīte, Baiba
Irmejs, Arvīds
Maksimenko, Jeļena
Loža, Pēteris
Trofimovičs, Genādijs
Miklaševičs, Edvīns
Nazarovs, Jurijs
Romanovska, Māra
Deičmane, Justīne
Irmejs, Reinis
Purkalne, Gunta
Gardovskis, Jānis
Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers
title Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers
title_full Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers
title_fullStr Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers
title_full_unstemmed Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers
title_short Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers
title_sort ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with brca1/2 pathogenic variant carriers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262039/
https://www.ncbi.nlm.nih.gov/pubmed/34233740
http://dx.doi.org/10.1186/s13053-021-00187-w
work_keys_str_mv AT licitebaiba ultrasoundguidedneedlebiopsyofaxillatoevaluatenodalmetastasisafterpreoperativesystemictherapyincohortof106breastcancersenrichedwithbrca12pathogenicvariantcarriers
AT irmejsarvids ultrasoundguidedneedlebiopsyofaxillatoevaluatenodalmetastasisafterpreoperativesystemictherapyincohortof106breastcancersenrichedwithbrca12pathogenicvariantcarriers
AT maksimenkojelena ultrasoundguidedneedlebiopsyofaxillatoevaluatenodalmetastasisafterpreoperativesystemictherapyincohortof106breastcancersenrichedwithbrca12pathogenicvariantcarriers
AT lozapeteris ultrasoundguidedneedlebiopsyofaxillatoevaluatenodalmetastasisafterpreoperativesystemictherapyincohortof106breastcancersenrichedwithbrca12pathogenicvariantcarriers
AT trofimovicsgenadijs ultrasoundguidedneedlebiopsyofaxillatoevaluatenodalmetastasisafterpreoperativesystemictherapyincohortof106breastcancersenrichedwithbrca12pathogenicvariantcarriers
AT miklasevicsedvins ultrasoundguidedneedlebiopsyofaxillatoevaluatenodalmetastasisafterpreoperativesystemictherapyincohortof106breastcancersenrichedwithbrca12pathogenicvariantcarriers
AT nazarovsjurijs ultrasoundguidedneedlebiopsyofaxillatoevaluatenodalmetastasisafterpreoperativesystemictherapyincohortof106breastcancersenrichedwithbrca12pathogenicvariantcarriers
AT romanovskamara ultrasoundguidedneedlebiopsyofaxillatoevaluatenodalmetastasisafterpreoperativesystemictherapyincohortof106breastcancersenrichedwithbrca12pathogenicvariantcarriers
AT deicmanejustine ultrasoundguidedneedlebiopsyofaxillatoevaluatenodalmetastasisafterpreoperativesystemictherapyincohortof106breastcancersenrichedwithbrca12pathogenicvariantcarriers
AT irmejsreinis ultrasoundguidedneedlebiopsyofaxillatoevaluatenodalmetastasisafterpreoperativesystemictherapyincohortof106breastcancersenrichedwithbrca12pathogenicvariantcarriers
AT purkalnegunta ultrasoundguidedneedlebiopsyofaxillatoevaluatenodalmetastasisafterpreoperativesystemictherapyincohortof106breastcancersenrichedwithbrca12pathogenicvariantcarriers
AT gardovskisjanis ultrasoundguidedneedlebiopsyofaxillatoevaluatenodalmetastasisafterpreoperativesystemictherapyincohortof106breastcancersenrichedwithbrca12pathogenicvariantcarriers